keyword
MENU ▼
Read by QxMD icon Read
search

Metaplastic breast cancer

keyword
https://www.readbyqxmd.com/read/27904534/metaplastic-breast-cancer-with-rapidly-progressive-recurrence-in-a-young-woman-case-report-and-review-of-the-literature
#1
Jerzy W Mituś, Beata Sas-Korczyńska, Anna Kruczak, Marek Jasiówka, Janusz Ryś
No abstract text is available yet for this article.
December 1, 2016: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/27895758/metaplastic-carcinoma-of-the-breast-imaging-and-pathological-features
#2
Tiantian Bian, Qing Lin, Zengjie Wu, Chunxiao Cui, Chunhua Qi, Li Li, Xiaohui Su
Metaplastic carcinoma of the breast is a rare form of breast cancer. The aim of the present study was to investigate the imaging and pathological features of metaplastic carcinoma. The features identified on mammography and sonography were retrospectively reviewed in 13 women with metaplastic carcinoma of the breast. The results from the mammographs and sonographs were additionally evaluated using immunohistochemical staining for the expression of the estrogen receptor (ER) and progesterone receptor (PR), receptor tyrosine-protein kinase erbB-2 (CerbB-2) and P53...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27893038/targeting-the-pi3k-akt-mtor-pathway-for-the-treatment-of-mesenchymal-triple-negative-breast-cancer-evidence-from-a-phase-1-trial-of-mtor-inhibition-in-combination-with-liposomal-doxorubicin-and-bevacizumab
#3
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, Thorunn Helgason, Daniel D Karp, Funda Meric-Bernstam, Kenneth R Hess, Shelley M Herbrich, Vicente Valero, Constance Albarracin, Jennifer K Litton, Mariana Chavez-MacGregor, Nuhad K Ibrahim, James L Murray, Kimberly B Koenig, David Hong, Vivek Subbiah, Razelle Kurzrock, Filip Janku, Stacy L Moulder
Importance: Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response. Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy...
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27819674/mmtv-cre-ccn6-knockout-mice-develop-tumors-recapitulating-human-metaplastic-breast-carcinomas
#4
E E Martin, W Huang, T Anwar, C Arellano-Garcia, B Burman, J-L Guan, M E Gonzalez, C G Kleer
Metaplastic breast carcinoma is an aggressive form of invasive breast cancer with histological evidence of epithelial to mesenchymal transition (EMT). However, the defining molecular events are unknown. Here we show that CCN6 (WISP3), a secreted matricellular protein of the CCN (CYR61/CTGF/NOV) family, is significantly downregulated in clinical samples of human spindle cell metaplastic breast carcinoma. We generated a mouse model of mammary epithelial-specific Ccn6 deletion by developing a floxed Ccn6 mouse which was bred with an MMTV-Cre mouse...
November 7, 2016: Oncogene
https://www.readbyqxmd.com/read/27738308/response-to-apatinib-in-chemotherapy-failed-advanced-spindle-cell-breast-carcinoma
#5
Na Zhou, Cong Min Liu, He Lei Hou, Chuan Tao Zhang, Dong Liu, Guan Qun Wang, Ke Wei Liu, Jing Juan Zhu, Hong Ying Lv, Tian Jun Li, Xiaochun Zhang
Spindle cell carcinoma of the breast is a rare subtype of metaplastic carcinoma, and no effective chemotherapy special for metaplastic carcinoma exists until now. As spindle cell carcinomas of the breast are typically "Triple Negative", endocrine therapy and molecular therapy targeted to Her2 might not be favorable, resulting in poor prognosis. Apatinib is currently being tested in patients with breast or lung cancers. Here we report a successful case using Apatinib to treat spindle cell carcinoma of breast...
October 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27697421/carcinosarcoma-of-the-breast-an-aggressive-subtype-of-metaplastic-cancer-report-of-a-rare-case-in-a-young-brca-1-mutated-woman
#6
Matteo Ghilli, Donatella M Mariniello, Giovanni Fanelli, Francesca Cascione, Andrea Fontana, Agostino Cristaudo, Anna Cilotti, Adelaide M Caligo, Giampiero Manca, Livio Colizzi, Antonio G Naccarato, Manuela Roncella
No abstract text is available yet for this article.
August 30, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27659377/paraneoplastic-polymyositis-presenting-as-a-clinically-occult-breast-cancer
#7
N Merali, M Yousuff, V Pronisceva, A Poddar
Paraneoplastic syndrome affects less than 1% of cancer patients. Diagnosis of paraneoplastic syndrome with neurological presentation requires screening for an underlying malignancy, including a complete history, physical examination and imaging studies. Treatment often results in symptom stability, rather than improvement. Paraneoplastic polymyositis can precede or instantaneously occur at diagnosis or treatment of a primary tumour, while neurological symptoms can persist even following cancer treatment. We report a rare case of metaplastic breast carcinoma with an unusual presentation of paraneoplastic polymyositis...
September 23, 2016: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/27626636/spock1-is-a-novel-transforming-growth-factor-%C3%AE-induced-myoepithelial-marker-that-enhances-invasion-and-correlates-with-poor-prognosis-in-breast-cancer
#8
Li-Ching Fan, Yung-Ming Jeng, Yueh-Tong Lu, Huang-Chun Lien
In addition to contraction, myoepithelia have diverse paracrine effects, including a tumor suppression effect. However, certain myoepithelial markers have been shown to contribute to tumor progression. Transforming growth factor-β (TGF-β) is involved in the transdifferentiation of fibroblasts to contractile myofibroblasts. We investigated whether TGF-β can upregulate potential myoepithelial markers, which may have functional and clinicopathological significance in breast cancer. We found that TGF-β induced SPOCK1 expression in MCF10A, MCF12A, and M10 breast cells and demonstrated SPOCK1 as a novel myoepithelial marker that was immunolocalized within or beneath myoepithelia lining ductolobular units...
2016: PloS One
https://www.readbyqxmd.com/read/27583878/features-of-triple-negative-breast-cancer-analysis-of-38-813-cases-from-the-national-cancer-database
#9
Magdalena L Plasilova, Brandon Hayse, Brigid K Killelea, Nina R Horowitz, Anees B Chagpar, Donald R Lannin
The aim of this study was to determine the features of triple-negative breast cancer (TNBC) using a large national database. TNBC is known to be an aggressive subtype, but national epidemiologic data are sparse. All patients with invasive breast cancer and known molecular subtype diagnosed in 2010 to 2011 were identified from the National Cancer Data Base (NCDB). Patients with and without TNBC were compared with respect to their sociodemographic and clinicopathologic features. TNBC was present in 38,628 of 295,801 (13%) female patients compared to 185 of 3136 (6%) male patients (P < 0...
August 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27568101/metaplastic-breast-cancer-molecular-typing-and-identification-of-potential-targeted-therapies-at-a-single-institution
#10
Jessica Edenfield, Christine Schammel, Justin Collins, David Schammel, W Jeff Edenfield
INTRODUCTION: Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic subtype of breast cancer comprising approximately 0.5% to 5.0% of all invasive breast cancers with a poor prognosis and limited therapeutic options. PATIENTS AND METHODS: We investigated MBC at our institution to evaluate outcomes and investigate the molecular profile of our cohort to determine the presence of mutations for which there are targeted therapies. RESULTS: We found our cohort to consist mainly of the matrix-producing variant (72%) with 48% having the stereotypical estrogen receptor-negative/progesterone receptor-negative/human epidermal growth factor receptor-2-negative phenotype...
July 25, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27531819/comprehensive-profiling-of-metaplastic-breast-carcinomas-reveals-frequent-overexpression-of-programmed-death-ligand-1
#11
Upasana Joneja, Semir Vranic, Jeffrey Swensen, Rebecca Feldman, Wangjuh Chen, Jeffrey Kimbrough, Nianqing Xiao, Sandeep Reddy, Juan Palazzo, Zoran Gatalica
AIMS: Metaplastic breast carcinoma (MBC) is a rare subtype of breast carcinoma less responsive to conventional chemotherapy than ductal carcinoma. In molecular terms, MBCs usually cluster with triple-negative breast cancers (TNBCs), but have a worse prognosis than TNBCs. Studies investigating MBCs for specific biomarkers of therapy response are rare and limited by the methodological approaches. The aim of the present study was to characterise MBCs on a molecular level and test programmed death-ligand 1 (PD-L1) biomarker expression in MBCs for future therapeutic interventions...
August 16, 2016: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27431460/management-and-outcomes-in-metaplastic-breast-cancer
#12
REVIEW
Ioannis-Georgios Tzanninis, Elias A Kotteas, Ioannis Ntanasis-Stathopoulos, Panagiota Kontogianni, George Fotopoulos
Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its management a challenge. Thus, the scope of the present review is to discuss the current therapeutic strategies for MBC in clinical practice and the corresponding outcomes and to suggest possible directions for future research...
December 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27424438/-metaplastic-carcinoma-of-the-breast-and-the-impact-of-the-p63-and-cytokeratin-5-6-experience-of-40-patients
#13
S Sherwell-Cabello, A Maffuz-Aziz, B Hernández-Hernández, V Bautista-Piña, S Labastida-Almendaro, S Rodríguez-Cuevas
BACKGROUND: Metaplasic carcinoma of the breast was initially described by Huvos in 1974. It is a rare and aggressive entity characterized by the presence of mesenchymal and epithelial components. OBJECTIVE: To know the incidence and biologic behaviour of the metaplasic carcinoma of the breast at the Instituto de Enfermedades de la Mama, FUCAM, AC. METHODS: Data on women diagnosed with metaplasic carcinoma of the breast between January 2005 and December 2014 was collected by retrospectively reviewing in FUCAM...
March 2016: Ginecología y Obstetricia de México
https://www.readbyqxmd.com/read/27250894/metaplastic-carcinoma-of-breast-a-case-series-of-seven-patients-from-a-tertiary-care-center-and-review-of-literature
#14
R Benson, R Madan, P K Julka, G K Rath
PURPOSE: Metaplastic carcinoma of breast (MCB) is a rare histological subtype of breast carcinoma and accounts for less than 1 percent of the total breast cancer cases. Here we are reporting a series of seven patients of MCB from single institute along with review of literature. MATERIAL AND METHODS: Patients records from January 2008 to August 2014 were retrieved to search for MCB patients. A etrospective review was conducted to document the clinicopathological features, treatment and outcomes of these patients...
May 2016: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/27245135/imaging-overview-of-metaplastic-carcinomas-of-the-breast-a-large-study-of-71-cases
#15
Fiona Langlands, Eleanor Cornford, Emad Rakha, Barbara Dall, Eleanor Gutteridge, David Dodwell, Abeer M Shaaban, Nisha Sharma
OBJECTIVES: To review the clinical presentation, baseline imaging features, surgical management and final surgical pathology of metaplastic carcinoma of the breast. METHODS: A total of 71 cases were identified over a 10year period from two major UK breast cancer institutions. Imaging at diagnosis including mammography, ultrasound, MRI and CT scans and histological diagnosis were reviewed. Follow-up data including local and systemic recurrence was retrieved. RESULTS: Of the 71 cases, 60(84...
June 1, 2016: British Journal of Radiology
https://www.readbyqxmd.com/read/27220763/prognostic-factors-in-the-myoepithelial-like-spindle-cell-type-of-metaplastic-breast-cancer
#16
Fabian Leo, Stephan Bartels, Lavinia Mägel, Theodor Framke, Guntram Büsche, Danny Jonigk, Matthias Christgen, Ulrich Lehmann, Hans Kreipe
Metaplastic breast carcinoma (MBC) comprises a heterogeneous group of tumors with difficult to predict biological behavior. A subset of MBC, characterized by spindle-shaped tumor cells with a myoepithelial-like immunophenotype, was entered into a retrospective study (n = 42, median follow-up time 43 months). Molecular parameters (DNA sequences of mutation hot spots in AKT1, ALK, APC, BRAF, CDH1, CTNNB1, EGFR, ERBB2, FBXW7, FGFR2, FOXL2, GNAQ, GNAS, KIT, KRAS, MAP2K1, MET, MSH6, NRAS, PDGFRA, PIK3CA, PTEN, SF3B1, SMAD4, SRC, SRSF2, STK11, TP53, and U2AF1; copy numbers for EGFR, c-myc, FGFR, PLAG, c-met) were assessed...
August 2016: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/27124919/a-clinicopathologic-analysis-of-45-patients-with-metaplastic-breast-carcinoma
#17
Ashley Cimino-Mathews, Sangita Verma, Maria Cristina Figueroa-Magalhaes, Stacie C Jeter, Zhe Zhang, Pedram Argani, Vered Stearns, Roisin M Connolly
OBJECTIVES: Metaplastic breast carcinomas (MBCs) are rare, aggressive cancers lacking targeted therapy. Here, we review the clinicopathologic features, treatment, and outcomes of patients with MBC treated at our institution. METHODS: We searched clinical and pathology databases for patients with histologically confirmed MBC from 1999 to 2012. We estimated survival probabilities using the Kaplan-Meier method and evaluated prognostic factors using Cox regression. RESULTS: Forty-five cases were identified, including chondroid (24%), spindled (20%), sarcomatoid (16%), squamous (11%), and mixed (29%) histologic subtypes...
March 2016: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27063096/elevated-hmga2-expression-is-associated-with-cancer-aggressiveness-and-predicts-poor-outcome-in-breast-cancer
#18
Jingjing Wu, Shizhen Zhang, Jinlan Shan, Zujian Hu, Xiyong Liu, Lirong Chen, Xingchang Ren, Lifang Yao, Hongqiang Sheng, Ling Li, David Ann, Yun Yen, Jian Wang, Xiaochen Wang
High mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological processes and is upregulated in several tumors. Here, we collected 273 breast cancer (BC) specimens as a training set and 310 specimens as a validation set to examine the expression of HMGA2 by immunohistochemical staining. It was found that HMGA2 expression was significantly positively correlated with advanced tumor grade and poor survival. Subgroup analysis indicated that high level of HMGA2 was significantly correlated with poor prognosis, especially in the subgroups of stage II-III, low pathological grade and non-triple negative breast cancer cases...
July 1, 2016: Cancer Letters
https://www.readbyqxmd.com/read/27062316/effect-of-neoadjuvant-chemotherapy-on-breast-cancer-phenotype-er-pr-and-her2-expression-implications-for-the-practising-oncologist
#19
Renu Gahlaut, Aneliese Bennett, Hiba Fatayer, Barbara J Dall, Nisha Sharma, Galina Velikova, Tim Perren, David Dodwell, Mark Lansdown, Abeer M Shaaban
PURPOSE: To assess the effect of neoadjuvant chemotherapy (NACT) on breast cancer characteristics, hormone receptors and human epidermal growth factor receptor 2 (HER2) expression and whether testing should be repeated on residual tumours. MATERIAL AND METHODS: Patients with primary operable breast cancer who received NACT at a single United Kingdom tertiary referral centre were included. Tumour type, grade (including details of mitotic grade, tubule formation and pleomorphism), oestrogen receptor (ER), progesterone receptor (PR) and HER2 status were compared between pre-treatment and post-treatment residual samples using tissue microarrays...
June 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27056619/anti-3-18f-facbc-18f-fluciclovine-pet-ct-of-breast-cancer-an-exploratory-study
#20
Funmilayo I Tade, Michael A Cohen, Toncred M Styblo, Oluwaseun A Odewole, Anna I Holbrook, Mary S Newell, Bital Savir-Baruch, Xiaoxian Li, Mark M Goodman, Jonathon A Nye, David M Schuster
UNLABELLED: The purpose of this study was to explore the uptake of the synthetic amino acid analog PET radiotracer anti-3-(18)F-FACBC ((18)F-fluciclovine) in breast lesions with correlation to histologic and immunohistochemical characteristics. METHODS: Twelve women with breast lesions underwent 45-min dynamic PET/CT of the thorax after intravenous administration of 366.3 ± 14.8 (337.44-394.05) MBq of (18)F-fluciclovine. Uptake in the primary lesions at 4 representative time points (5, 17, 29, and 41 min) after injection were correlated with histologic, imaging, and clinical findings...
September 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
14705
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"